Ignite Creation Date:
2024-05-05 @ 11:45 AM
Last Modification Date:
2024-10-26 @ 9:13 AM
Study NCT ID:
NCT00125684
Status:
COMPLETED
Last Update Posted:
2012-01-19
First Post:
2005-07-29
Brief Title:
Bioavailability and Effectiveness of Transdermally Administered Morphine
Sponsor:
Alberta Health services
Organization:
AHS Cancer Control Alberta
Study Overview
Official Title:
Bioavailability and Effectiveness of Transdermally Administered Morphine
Status:
COMPLETED
Status Verified Date:
2011-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Patients will participate in two arms of the trial one in which morphine will be administered transdermally and after a 3 day wash out period one in which morphine will be administered subcutaneously
Detailed Description:
Patients will participate in two arms of the trial one in which morphine will be administered transdermally and after a 3 day wash out period one in which morphine will be administered subcutaneously Blood draws will be done after both dosing methods in order to compare blood levels of morphine by the different routes
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None